American Society of Clinical Oncology & Merck & Co.

American Society of Clinical Oncology: The American Society of Clinical Oncology>>> Annual Meeting served as the platform for presenting the significant research findings on GLP-1 receptor agonist and breast cancer prevention.

Merck & Co.: Merck & Co.>>>'s immunotherapy Keytruda is mentioned as potentially faring better when patients are also taking GLP-1 drugs, suggesting a possible interaction with the immune system.

American Society of Clinical Oncology: The American Society of Clinical Oncology>>> is hosting the presentation of the trial results, solidifying its role as a central platform for disseminating significant cancer research. This event enhances its prestige and influence within the oncology community.

Merck & Co.: As the manufacturer of pembrolizumab (Keytruda), Merck & Co.>>> benefits from the combination therapy's success, as it reinforces the drug's role as a standard of care and expands its potential market in combination with intismeran. The positive results could lead to continued strong sales for pembrolizumab.

American Society of Clinical Oncology: The organization hosted the annual meeting where the Phase III clinical study results were presented as an oral presentation, providing a platform for dissemination of the findings.

Merck & Co.: As the licensee for sac-TMT outside Greater China, the positive clinical trial results for sac-TMT in combination with its drug pembrolizumab (KEYTRUDA) validate its investment and expand its oncology portfolio.